MoA for Antibody-Drug Conjugate Targeting TGF-β

MoA for Antibody-Drug Conjugate Targeting TGF-β

MoA for Antibody-Drug Conjugate Targeting TGF-β

MoA for an
Antibody-Drug Conjugate
Targeting TGF-β

Client:

Bicara Therapeutics is a clinical-stage biopharmaceutical company pioneering bifunctional antibody therapies for solid tumors. Their lead program, ficerafusp alfa (BCA101), is designed to simultaneously block tumor-promoting pathways and activate the immune system by targeting EGFR and neutralizing TGF-β. By combining targeted delivery with immune modulation, Bicara aims to improve treatment efficacy and overcome resistance in cancer therapy. The company is backed by leading investors and continues to advance innovative solutions in oncology.

Bicara Therapeutics is a clinical-stage biopharmaceutical company pioneering bifunctional antibody therapies for solid tumors. Their lead program, ficerafusp alfa (BCA101), is designed to simultaneously block tumor-promoting pathways and activate the immune system by targeting EGFR and neutralizing TGF-β. By combining targeted delivery with immune modulation, Bicara aims to improve treatment efficacy and overcome resistance in cancer therapy. The company is backed by leading investors and continues to advance innovative solutions in oncology.

Bicara Therapeutics is a clinical-stage biopharmaceutical company pioneering bifunctional antibody therapies for solid tumors. Their lead program, ficerafusp alfa (BCA101), is designed to simultaneously block tumor-promoting pathways and activate the immune system by targeting EGFR and neutralizing TGF-β. By combining targeted delivery with immune modulation, Bicara aims to improve treatment efficacy and overcome resistance in cancer therapy. The company is backed by leading investors and continues to advance innovative solutions in oncology.

Bicara Therapeutics is a clinical-stage biopharmaceutical company pioneering bifunctional antibody therapies for solid tumors. Their lead program, ficerafusp alfa (BCA101), is designed to simultaneously block tumor-promoting pathways and activate the immune system by targeting EGFR and neutralizing TGF-β. By combining targeted delivery with immune modulation, Bicara aims to improve treatment efficacy and overcome resistance in cancer therapy. The company is backed by leading investors and continues to advance innovative solutions in oncology.

Client:

Project Goal

Project Goal

Project Goal

Project Goal

Bicara Therapeutics needed a concise and visually compelling way to communicate the dual mechanism of action of its antibody–drug conjugate, which targets EGFR and neutralizes TGF-β in solid tumors. The goal was to illustrate how this therapy not only directly inhibits tumor growth but also remodels the tumor microenvironment—enhancing effector immune cells, reducing regulatory immune cells, and promoting anti-tumor immunity. The animation, developed in parallel with a static infographic, was intended for use on Bicara’s website and in corporate presentations, making it essential to balance scientific accuracy with visual clarity and accessibility.

Bicara Therapeutics needed a concise and visually compelling way to communicate the dual mechanism of action of its antibody–drug conjugate, which targets EGFR and neutralizes TGF-β in solid tumors. The goal was to illustrate how this therapy not only directly inhibits tumor growth but also remodels the tumor microenvironment—enhancing effector immune cells, reducing regulatory immune cells, and promoting anti-tumor immunity. The animation, developed in parallel with a static infographic, was intended for use on Bicara’s website and in corporate presentations, making it essential to balance scientific accuracy with visual clarity and accessibility.

Bicara Therapeutics needed a concise and visually compelling way to communicate the dual mechanism of action of its antibody–drug conjugate, which targets EGFR and neutralizes TGF-β in solid tumors. The goal was to illustrate how this therapy not only directly inhibits tumor growth but also remodels the tumor microenvironment—enhancing effector immune cells, reducing regulatory immune cells, and promoting anti-tumor immunity. The animation, developed in parallel with a static infographic, was intended for use on Bicara’s website and in corporate presentations, making it essential to balance scientific accuracy with visual clarity and accessibility.

Bicara Therapeutics needed a concise and visually compelling way to communicate the dual mechanism of action of its antibody–drug conjugate, which targets EGFR and neutralizes TGF-β in solid tumors. The goal was to illustrate how this therapy not only directly inhibits tumor growth but also remodels the tumor microenvironment—enhancing effector immune cells, reducing regulatory immune cells, and promoting anti-tumor immunity. The animation, developed in parallel with a static infographic, was intended for use on Bicara’s website and in corporate presentations, making it essential to balance scientific accuracy with visual clarity and accessibility.

Schematic 3D visualization of Tregs and M2 macrophages in the tumor microenvironment
Schematic 3D visualization of Tregs and M2 macrophages in the tumor microenvironment
Schematic 3D visualization of Tregs and M2 macrophages in the tumor microenvironment
Schematic 3D visualization of Tregs and M2 macrophages in the tumor microenvironment

Immune suppressive microenvironment with Regulatory T cells and M2 Tumor-associated Macrophages (TAM)

Immune suppressive microenvironment with Regulatory T cells and M2 Tumor-associated Macrophages (TAM)

Immune suppressive microenvironment with Regulatory T cells and M2 Tumor-associated Macrophages (TAM)

Immune suppressive microenvironment with Regulatory T cells and M2 Tumor-associated Macrophages (TAM)

TGF-β binds to TGF-βR on the tumor cells

TGF-β binds to TGF-βR on the tumor cells

TGF-β binds to TGF-βR on the tumor cells

TGF-β binds to TGF-βR on the tumor cells

Molecular visualization of the ficerafusp alpha antibody-drug conjugate
Molecular visualization of the ficerafusp alpha antibody-drug conjugate
Molecular visualization of the ficerafusp alpha antibody-drug conjugate
Molecular visualization of the ficerafusp alpha antibody-drug conjugate

Ficerafusp alfa

Ficerafusp alfa

Ficerafusp alfa

Ficerafusp alfa

“I liked working with the team and I enjoyed the creative process. Team worked well under tight timelines.  

The animation created by Visual Science clearly demonstrated the mechanism of action of our therapeutic within the context of a complex tumor microenvironment. This brought our story to life in a creative and visually stimulating way”

“I liked working with the team and I enjoyed the creative process. Team worked well under tight timelines.  

The animation created by Visual Science clearly demonstrated the mechanism of action of our therapeutic within the context of a complex tumor microenvironment. This brought our story to life in a creative and visually stimulating way”

“I liked working with the team and I enjoyed the creative process. Team worked well under tight timelines.  

The animation created by Visual Science clearly demonstrated the mechanism of action of our therapeutic within the context of a complex tumor microenvironment. This brought our story to life in a creative and visually stimulating way”

“I liked working with the team and I enjoyed the creative process. Team worked well under tight timelines.  

The animation created by Visual Science clearly demonstrated the mechanism of action of our therapeutic within the context of a complex tumor microenvironment. This brought our story to life in a creative and visually
stimulating way”

Patrick Hsu
Patrick Hsu
Patrick Hsu

Senior Director, Translational Medicine, Biomarkers, Immunotherapy

Senior Director, Translational Medicine,
Biomarkers, Immunotherapy

Shematic 3D visualization of the ficerafusp alpha binding to the EGFR within the tumor microenvironment
Shematic 3D visualization of the ficerafusp alpha binding to the EGFR within the tumor microenvironment
Shematic 3D visualization of the ficerafusp alpha binding to the EGFR within the tumor microenvironment
Shematic 3D visualization of the ficerafusp alpha binding to the EGFR within the tumor microenvironment

Ficerafusp alfa blocks both EGFR and TGF-β, aiming to remodel the tumor microenvironment

Ficerafusp alfa blocks both EGFR and TGF-β, aiming to remodel the tumor microenvironment

Ficerafusp alfa blocks both EGFR and TGF-β, aiming to remodel the tumor microenvironment

Ficerafusp alfa blocks both EGFR and TGF-β, aiming to remodel the tumor microenvironment

Schematic 3D rendering of the cancer-associated fibroblast in the TME
Schematic 3D rendering of the cancer-associated fibroblast in the TME
Schematic 3D rendering of the cancer-associated fibroblast in the TME
Schematic 3D rendering of the cancer-associated fibroblast in the TME

Cancer-Associated Fibroblasts (CAFs)

Cancer-Associated Fibroblasts (CAFs)

Cancer-Associated Fibroblasts (CAFs)

Cancer-Associated Fibroblasts (CAFs)

EGFR signaling blocked by Ficerafusp alfa

EGFR signaling blocked by Ficerafusp alfa

EGFR signaling blocked by Ficerafusp alfa

EGFR signaling blocked by Ficerafusp alfa

The Process

The Process

The Process

The Process

Animation type:

Animation type:

Animation type:

Animation type:

3D animation

3D animation

3D animation

3D animation

Project timline:

Project timline:

Project timline:

Project timline:

4 weeks

4 weeks

4 weeks

4 weeks

Review:

Review:

Review:

Review:

2 zoom calls + 5 e-mail feedback sessions

2 zoom calls + 5 e-mail feedback sessions

2 zoom calls + 5 e-mail feedback sessions

2 zoom calls + 5 e-mail feedback sessions

Team:

Find out which of our 26 scientific animation options works best for investor relations and communications:

Find out which of our 26 scientific animation options works best for investor relations and communications:

Find out which of our 26 scientific animation options works best for investor relations and communications:

Find out which of our 26 scientific animation options works best for investor relations and communications:

To deliver both scientific fidelity and production speed, we created the animation and infographic using a unified visual style. The same 3D models and visual elements were used across both formats, ensuring visual consistency. Camera movement and dynamic storytelling brought the infographic to life, maintaining continuity across media. We developed a unique animation format—Cellular 3D—that enabled schematic-level storytelling while preserving molecular accuracy. The final asset was optimized for cross-platform performance.


Cellular 3D Style: A hybrid approach combining infographic clarity with high-resolution 3D models of key molecules (EGFR, TGF-β, and the antibody–drug conjugate [ADC]).


Scientific Precision: Molecular components were modeled at atomic resolution, while supporting visuals remained clean and schematic.


Web Optimization: Delivered as a <5 MB file that autoplays without external players, ensuring mobile compatibility.


Brand Integration: Colors and visual styles were aligned with the client’s new branding in collaboration with their design agency.

Why did we use this
animation type?

Why did we use this
animation type?

Why did we use this
animation type?

Why did we use this
animation type?

The Cellular 3D format was chosen to balance scientific integrity with high-level storytelling. It provided a middle ground between simple 2D explainer videos and complex high-end 3D animations, enabling efficient production while still showcasing critical molecular interactions. This format was ideal for communicating complex mechanisms in a way that felt modern, on-brand, and informative—without overwhelming the audience.

The Cellular 3D format was chosen to balance scientific integrity with high-level storytelling. It provided a middle ground between simple 2D explainer videos and complex high-end 3D animations, enabling efficient production while still showcasing critical molecular interactions. This format was ideal for communicating complex mechanisms in a way that felt modern, on-brand, and informative—without overwhelming the audience.

The Cellular 3D format was chosen to balance scientific integrity with high-level storytelling. It provided a middle ground between simple 2D explainer videos and complex high-end 3D animations, enabling efficient production while still showcasing critical molecular interactions. This format was ideal for communicating complex mechanisms in a way that felt modern, on-brand, and informative—without overwhelming the audience.

The Cellular 3D format was chosen to balance scientific integrity with high-level storytelling. It provided a middle ground between simple 2D explainer videos and complex high-end 3D animations, enabling efficient production while still showcasing critical molecular interactions. This format was ideal for communicating complex mechanisms in a way that felt modern, on-brand, and informative—without overwhelming the audience.

Outcome:

Outcome:

Outcome:

Outcome:

The final animation successfully visualized Bicara’s bifunctional therapy in a manner that was both scientifically accurate and visually engaging. It aligned seamlessly with the accompanying static infographic, reinforced the company’s updated branding, and supported communication goals for investors and other stakeholders. The lightweight, web-friendly format made the asset easy to deploy across platforms, while the Cellular 3D style established a new visual standard for rapid, precise scientific storytelling.

The final animation successfully visualized Bicara’s bifunctional therapy in a manner that was both scientifically accurate and visually engaging. It aligned seamlessly with the accompanying static infographic, reinforced the company’s updated branding, and supported communication goals for investors and other stakeholders. The lightweight, web-friendly format made the asset easy to deploy across platforms, while the Cellular 3D style established a new visual standard for rapid, precise scientific storytelling.

The final animation successfully visualized Bicara’s bifunctional therapy in a manner that was both scientifically accurate and visually engaging. It aligned seamlessly with the accompanying static infographic, reinforced the company’s updated branding, and supported communication goals for investors and other stakeholders. The lightweight, web-friendly format made the asset easy to deploy across platforms, while the Cellular 3D style established a new visual standard for rapid, precise scientific storytelling.

The final animation successfully visualized Bicara’s bifunctional therapy in a manner that was both scientifically accurate and visually engaging. It aligned seamlessly with the accompanying static infographic, reinforced the company’s updated branding, and supported communication goals for investors and other stakeholders. The lightweight, web-friendly format made the asset easy to deploy across platforms, while the Cellular 3D style established a new visual standard for rapid, precise scientific storytelling.

Full animation

Full animation

Full animation

Full animation

Contact us

Contact us

Contact us

Contact us

Visual Science is an award-winning medical animation and digital scientific communications company, trusted by leading biotech and pharmaceutical organizations since 2007, including J&J, Pfizer, Novartis, Roche, Takeda, Gilead, AbbVie, and 100+ others.

We specialize in science-grade MoA and MoD videos, medical animation, and scientific storytelling, as well as digital and AI-driven solutions for Medical Affairs, marketing, corporate communications, and investor relations.

Contacts

US toll-free

1 888 374-16-95

NY

1 516 340-37-30

London

44 20 3734-2517

Address

200 Vesey Street, 24th floor,
New York, NY 10281, USA

Social networks

LinkedIn Logo
Vimeo Logo

© 2026, Visual Science. All rights reserved.

Privacy policy & Cookie policy

Visual Science is an award-winning medical animation and digital scientific communications company, trusted by leading biotech and pharmaceutical organizations since 2007, including J&J, Pfizer, Novartis, Roche, Takeda, Gilead, AbbVie, and 100+ others.

We specialize in science-grade MoA and MoD videos, medical animation, and scientific storytelling, as well as digital and AI-driven solutions for Medical Affairs, marketing, corporate communications, and investor relations.

Contacts

US toll-free

1 888 374-16-95

NY

1 516 340-37-30

London

44 20 3734-2517

Address

200 Vesey Street, 24th floor, New York, NY 10281, USA

© 2026, Visual Science. All rights reserved.

Privacy policy & Cookie policy

Visual Science is an award-winning medical animation and digital scientific communications company, trusted by leading biotech and pharmaceutical organizations since 2007, including J&J, Pfizer, Novartis, Roche, Takeda, Gilead, AbbVie, and 100+ others.

We specialize in science-grade MoA and MoD videos, medical animation, and scientific storytelling, as well as digital and AI-driven solutions for Medical Affairs, marketing, corporate communications, and investor relations.

Contacts

US toll-free

1 888 374-16-95

NY

1 516 340-37-30

London

44 20 3734-2517

Address

200 Vesey Street, 24th floor,
New York, NY 10281, USA

Social networks

LinkedIn Logo
Vimeo Logo

© 2026, Visual Science. All rights reserved.

Privacy policy & Cookie policy

Visual Science is an award-winning medical animation and digital scientific communications company, trusted by leading biotech and pharmaceutical organizations since 2007, including J&J, Pfizer, Novartis, Roche, Takeda, Gilead, AbbVie, and 100+ others.

We specialize in science-grade MoA and MoD videos, medical animation, and scientific storytelling, as well as digital and AI-driven solutions for Medical Affairs, marketing, corporate communications, and investor relations.

Contacts

US toll-free

1 888 374-16-95

NY

1 516 340-37-30

London

44 20 3734-2517

Address

200 Vesey Street, 24th floor,
New York, NY 10281, USA

Social networks

LinkedIn Logo
Vimeo Logo

© 2026, Visual Science. All rights reserved.

Privacy policy & Cookie policy

Visual Science Logo
Visual Science Logo
Visual Science Logo